gsk201604156k.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending April 2016
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 



                                                                                       GlaxoSmithKline plc
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons
 
In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 15 April 2016 that the following Directors and Persons Discharging Managerial Responsibilities ('PDMR') acquired GSK Ordinary Shares ('Shares') on 14 April 2016, at a price of 1500.59 pence per Share, as a result of the reinvestment of dividends paid on Shares held through GSK's ShareReward Plan:
 
 
Director/PDMR
 
Ordinary Shares
 
Sir Andrew Witty
 
92
 
Mr R G Connor
 
112
 
Mr S Dingemans
 
33
 
Mr N Hirons
 
8
 
Mr S A Hussain
 
20
 
Mr D S Redfern
 
129
 
Ms C Thomas
 
129
 
Mr P C Thomson
 
67
 
Dr P J T Vallance
 
75
 
Ms E Walmsley
 
22
 
Mrs V A Whyte
 
89
 
 
 
V A Whyte
Company Secretary
 
15 April 2016
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: April 12, 2016 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc